PL9655

PL9655 is a small molecule melanocortin receptor agonist, specifically targeting the melanocortin 1 receptor (MC1R) and also showing activity at the melanocortin 5 receptor (MC5R). It is being developed by Palatin Technologies for ophthalmic indications, with a primary focus on diabetic retinopathy. Preclinical studies have demonstrated that PL9655 downregulates inflammatory pathways, suppresses angiogenesis, stabilizes the blood-retinal barrier, reduces VEGF signaling, and protects retinal ganglion cells. These effects contribute to vision preservation and neuroprotection in models of diabetic retinopathy. The drug can be administered both topically and systemically, offering potential advantages over current therapies that require invasive delivery methods[2][3][5].